Natco Pharma Approves Rights Issue Of Up To ₹1,300 Crore

Board approved rights issue up to 1300 Cr of Rs2 shares; price, ratio, record date later. Deferred NCLT filing for crop demerger; to revise scheme post-rights to keep swap ratio. First concrete structure for the long-evaluated fundraise, opting for rights over QIP route; ties demerger timetable to completion of issue, pushing crop separation further out. Use of proceeds, pricing, entitlement ratio and timetable undisclosed; needs shareholder, regulatory nods. Rights choice limits dilution to existing holders if subscribed.